2018 · GS Paper 3 · Q15 · 15 marks

Why is there so much activity in the field of biotechnology in our country? How has this activity benefitted the field of biopharma?

In short

Biotechnology activity has surged in India because of sustained state support through DBT and BIRAC, a start-up ecosystem, cheap skilled research and strong global demand. Biopharma has gained most: India supplies 55-60% of UNICEF's vaccine volume and has produced indigenous vaccines, biosimilars and CAR-T therapy.

Model answer

Ghissu Editorial · Verified 4 Oct 2026

Introduction
India's bioeconomy grew at least tenfold between 2014 and 2022 and is projected to reach USD 300 billion by 2030 (RIS, 2025). Biopharma is its most visible beneficiary.
Why Biotechnology Activity Has Surged in India
•

Policy architecture

The Department of Biotechnology (1986), BIRAC (2012), the National Biopharma Mission (2017) and the BioE3 Policy (2024) fund research from lab to market.

•

Start-ups

BIRAC's BioNEST incubators have nurtured thousands of biotech start-ups, and the Bio-RIDE scheme (2024) extends that support.

•

Talent and cost

A large science workforce and low research costs draw firms such as Biocon and Syngene.

•

Demand pull

A heavy disease burden, expiring biologic patents and COVID-19 created domestic and export demand.

How the Activity Has Benefitted Biopharma
•

Vaccine leadership

India supplies 55-60% of UNICEF's vaccine volume (PIB, 2025), with indigenous Rotavac, Covaxin, ZyCoV-D and Cervavac.

•

Biosimilars

Biocon's trastuzumab biosimilar was the first approved by the US FDA (2017), cutting cancer-therapy costs.

•

Advanced therapies

NexCAR19 (2023), India's first indigenous CAR-T therapy, costs a fraction of the global price.

•

Industry scale

Biopharma earned about US$ 5.84 billion of pharma's US$ 56.97 billion turnover in 2024-25 (RIS).

Way Forward
•

Biopharma SHAKTI

Use the Budget 2026-27's Rs 10,000 crore initiative and 1,000 accredited trial sites to target 5% of the global market.

•

R&D and regulation

Raise R&D above 0.84% of GDP and equip CDSCO for faster biologic approvals.

Conclusion
State support, start-ups and global demand have fuelled biotechnology, and biopharma has turned that energy into affordable vaccines and therapies, advancing Atmanirbhar Bharat and SDG 3.

This model answer is indicative and the model can make mistakes; please verify key facts independently.

Hand-drawn diagram: From biotech push to biopharma gains. From biotech push to biopharma gains. Flow: DBT, BIRAC funding → Start-ups and talent → Vaccines, biosimilars → Affordable access → Global exports
Diagram: From biotech push to biopharma gains

Practise this question

  1. 1Get the answer sheet

    Sized for this question.

  2. 2Write your answer

    Timed, by hand.

  3. 3Get it marked

    Your score and what to fix.

Share this questionWhatsAppTelegramXLinkedIn

This chapter in the exam

Bio-technology7 questions

Asked in 7 of 14 sittings since 2013

2013
–
2014
–
2015
–
2016
–
2017
1
2018
1
2019
1
2020
–
2021
1
2022
1
2023
1
2024
–
2025
–
2026
1

All 7 questions, sorted by sub-topic, with model answers and practice.

Question from the official UPSC Civil Services (Main) Examination 2018 paper. Answer written by Ghissu's engine and checked against our editorial standards. Found an error? Tell us and we correct it within 48 hours.

Ghissu

OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·
OUTWORK·
OUTTHINK·
MASTER THE SYSTEM·